Skip to main content
. 2021 Mar 30;65(4):413–429. doi: 10.1165/rcmb.2021-0010OC

Figure 7.

Figure 7.

Attenuation of H + C MDM EVs mediated cardiopulmonary dysfunction in the presence of TGFβ-RI In. HIV-Tg or WT rats were IV injected with four doses of H + C MDM EVs (10 μg each at a 5-d interval) in the presence of treatment with TGFβ receptor In.: GW788388 (1 mg/kg/d) or vehicle, once daily orally for 21 days. (A) RVSP in WT and HIV-Tg rats given H + C EVs with and without In. in comparison with WT rats treated with Con EVs (n = 5/group). (B) RVEDA at Day 0 and Day 21 for WT and HIV-Tg rats given H + C EVs in the presence or absence of GW788388. (C and D) Percent change in RV/LV EDA (C) and EF (D) in rats on treatment with or without GW788388. (E) ELISAs were performed to assess serum levels of endothelin-1, TNF-α, and cardiac troponin-I. Box and whisker plots show the median value and 10th to 90th percentiles. @@P < 0.01 and @@@P < 0.001 versus WT Con EVs; *P < 0.05, **P < 0.01, and ***P < 0.001 versus WT H + C EVs; and $$P < 0.01 and $$$P < 0.001 versus HIV-Tg H + C EVs. EDA = end-diastolic area; EF = ejection fraction; RVEDA = EDA of RV.